Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis
- 45 Downloads
The aim of the study is to evaluate the performance of extreme patient-reported outcomes (PRO) against definitions of fibromyalgia (FM) in patients with axial spondyloarthritis (axSpA).
Ancillary analysis of the Predict-SpA trial, an observational study of axSpA patients receiving TNF-α inhibitor, was performed. ‘Extreme PRO’ was defined as a score ≥ 8 on three out of the first five Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions (scored 0–10). FM was defined by the American College of Rheumatology (ACR) 1990 criteria and the Fibromyalgia Rapid Screening Test (FiRST). Performances of ‘extreme PRO’ for FM were evaluated by the sensitivity, specificity and positive likelihood ratio using the 1990 ACR criteria as gold standard. As secondary analysis, the FiRST was used as the external standard.
The prevalence of ‘extreme PRO’ in this population was 28.8% at baseline and decreased to 9.9% at 12 weeks. ‘Extreme PRO’ had low sensitivity 12 weeks after TNF initiation (0.18, 95% confidence interval [CI] 0.10–0.27 vs 0.60, 95% CI 0.50–0.71, at baseline), but high specificity (0.92, 95% CI 0.89–0.94 vs 0.78, 95% 0.74–0.82, at baseline), using ACR 1990 criteria as gold standard. Performances when tested against FiRST at 12 weeks showed higher sensitivity (0.27, 95% CI 0.20–0.35) and specificity (0.96, 95% CI 0.94–0.98).
The proposed extreme PRO definition showed great specificity for FM recognition in patients with axSpA, suggesting it could be used in observational studies when specific items for FM classification are not available.
KeywordsPatient-reported outcomes BASDAI Fibromyalgia Spondyloarthritis
This study was conducted thanks to an unrestricted grant from MSD.
Compliance with ethical standards
Conflict of interest
None of the authors has any conflicts of interest to declare for the present study.
CPP Île de France 3 - date 24/10/2014. The manuscript has been read and approved by all the authors and we confirm that each individual named as an author meets the journal’s criteria for authorship.
- 4.Perrot S, Peixoto M, Dieude P, Hachulla E, Avouac J, Ottaviani S et al (2017) Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. Clin Exp Rheumatol 35(3):35–42Google Scholar
- 9.Almodovar R, Carmona L, Zarco P, Collantes E, González C, Mulero J et al. Fibromyalgia in patients with ankylosing spondylitis: Prevalence and utility of the measures of activity, function and radiological damage. Clin Exp Rheumatol. 2010;28:63.Google Scholar
- 18.Zochling J (2011) Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Sp. Arthritis Care Res 63:11CrossRefGoogle Scholar
- 19.Dougados M, Logeart I, Szumski A, Coindreau J, Jones H (2017) Evaluation of whether extremely high enthesitis or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores suggest fibromyalgia and confound the anti-TNF response in early non-radiographic axial spondyloarthritis. Clin Exp Rheumatol 35:50–53Google Scholar
- 20.Meghnathi B, Etcheto A, Claudepierre P, Dougados M, Moltό A (2017) SAT0386 Extreme patient reported outcome (PRO) in early spondyloarthritis: a surrogate for fibromyalgia? its impact on TNF-ALPHA blockers treatment effect? Ann Rheum Dis 76(Suppl 2):917–918Google Scholar